Covered recipient · General Payments record
MUSHARRAF NAVAID
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$5,378.35
- Reported across 328 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $229.96 | 13 |
| Education | $69.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $69.99 | 1 |
| PFIZER INC. | $65.39 | 5 |
| Merck Sharp & Dohme Corporation | $41.19 | 2 |
| Sumitomo Pharma America, Inc. | $24.45 | 1 |
| Exelixis Inc. | $23.53 | 1 |
| Tempus AI, Inc | $23.03 | 1 |
| Gilead Sciences, Inc. | $18.85 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.82 | 1 |
| SERVIER PHARMACEUTICALS LLC | $14.70 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $69.99 | 06/07/2024 | Education | Undisputed | 01/23/2026 | 1139339990 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.82 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101595737 | CMS |
| Exelixis Inc. | $23.53 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138562622 | CMS |
| Gilead Sciences, Inc. | $18.85 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133795625 | CMS |
| Merck Sharp & Dohme LLC | $25.36 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141915169 | CMS |
| Merck Sharp & Dohme LLC | $15.83 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141834875 | CMS |
| PFIZER INC. | $3.77 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131231016 | CMS |
| PFIZER INC. | $3.16 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131231020 | CMS |
| PFIZER INC. | $19.82 | 04/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131298136 | CMS |
| PFIZER INC. | $21.34 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131513415 | CMS |
| PFIZER INC. | $17.30 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131253096 | CMS |
| SERVIER PHARMACEUTICALS LLC | $14.70 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147262214 | CMS |
| Sumitomo Pharma America, Inc. | $24.45 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148895479 | CMS |
| Tempus AI, Inc | $23.03 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150170610 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.